- Home
- CMA vs TECH Comparison
CMA vs TECH Comparison
Compare CMA & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- TECH
- Stock Information
- Founded
- CMA 1849
- TECH 1976
- Country
- CMA United States
- TECH United States
- Employees
- CMA N/A
- TECH N/A
- Industry
- CMA Major Banks
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMA Finance
- TECH Health Care
- Exchange
- CMA Nasdaq
- TECH Nasdaq
- Market Cap
- CMA 7.1B
- TECH 7.8B
- IPO Year
- CMA N/A
- TECH 1989
- Fundamental
- Price
- CMA $56.17
- TECH $46.78
- Analyst Decision
- CMA Hold
- TECH Buy
- Analyst Count
- CMA 20
- TECH 10
- Target Price
- CMA $61.55
- TECH $73.44
- AVG Volume (30 Days)
- CMA 1.3M
- TECH 2.2M
- Earning Date
- CMA 07-18-2025
- TECH 05-07-2025
- Dividend Yield
- CMA 5.05%
- TECH 0.68%
- EPS Growth
- CMA 4.95
- TECH N/A
- EPS
- CMA 5.29
- TECH 0.83
- Revenue
- CMA $3,234,000,000.00
- TECH $1,208,770,000.00
- Revenue This Year
- CMA $7.20
- TECH $7.16
- Revenue Next Year
- CMA $3.01
- TECH $6.36
- P/E Ratio
- CMA $10.64
- TECH $56.37
- Revenue Growth
- CMA N/A
- TECH 4.72
- 52 Week Low
- CMA $45.32
- TECH $46.01
- 52 Week High
- CMA $73.45
- TECH $83.96
- Technical
- Relative Strength Index (RSI)
- CMA 49.43
- TECH 39.97
- Support Level
- CMA $57.70
- TECH $46.05
- Resistance Level
- CMA $59.13
- TECH $49.92
- Average True Range (ATR)
- CMA 1.08
- TECH 2.20
- MACD
- CMA -0.02
- TECH -0.04
- Stochastic Oscillator
- CMA 35.43
- TECH 8.74
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.